{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T14:47:08Z","timestamp":1761490028597},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,6,10]],"date-time":"2016-06-10T00:00:00Z","timestamp":1465516800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1007\/s00280-016-3078-7","type":"journal-article","created":{"date-parts":[[2016,6,10]],"date-time":"2016-06-10T20:24:37Z","timestamp":1465590277000},"page":"183-189","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Effect of renal function on pemetrexed-induced haematotoxicity"],"prefix":"10.1007","volume":"78","author":[{"given":"Yosuke","family":"Ando","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moeko","family":"Ujita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumie","family":"Murai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Ohta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaori","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teppei","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minori","family":"Funatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuyoshi","family":"Imaizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenji","family":"Kawada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimio","family":"Yasuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,10]]},"reference":[{"key":"3078_CR1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S1470-2045(09)70364-X","volume":"11","author":"T Mitsudomi","year":"2010","unstructured":"Mitsudomi T, Morita S, Yatabe Y et al (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11:121\u2013128. doi: 10.1016\/S1470-2045(09)70364-X","journal-title":"Lancet Oncol"},{"key":"3078_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/S1470-2045(11)70393-X","volume":"13","author":"R Rosell","year":"2012","unstructured":"Rosell R, Carcereny E, Gervais R et al (2012) Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 13:239\u2013246. doi: 10.1016\/S1470-2045(11)70393-X","journal-title":"Lancet Oncol"},{"key":"3078_CR3","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S1470-2045(11)70184-X","volume":"12","author":"C Zhou","year":"2011","unstructured":"Zhou C, Wu YL, Chen G et al (2011) Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 12:735\u2013742. doi: 10.1016\/S1470-2045(11)70184-X","journal-title":"Lancet Oncol"},{"key":"3078_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1470-2045(13)70604-1","volume":"15","author":"YL Wu","year":"2014","unstructured":"Wu YL, Zhou C, Hu CP et al (2014) Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. Lancet Oncol 15:213\u2013222. doi: 10.1016\/S1470-2045(13)70604-1","journal-title":"Lancet Oncol"},{"key":"3078_CR5","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1200\/JCO.2012.44.2806","volume":"31","author":"LV Sequist","year":"2013","unstructured":"Sequist LV, Yang JC, Yamamoto N et al (2013) Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 31:3327\u20133334","journal-title":"J Clin Oncol"},{"key":"3078_CR6","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1056\/NEJMoa1214886","volume":"373","author":"AT Shaw","year":"2015","unstructured":"Shaw AT, Kim DW, Nakagawa K et al (2015) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 373:1582. doi: 10.1056\/NEJMoa1214886","journal-title":"N Engl J Med"},{"key":"3078_CR7","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/S1470-2045(13)70142-6","volume":"14","author":"T Seto","year":"2013","unstructured":"Seto T, Kiura K, Nishio M et al (2013) CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1\u20132 study. Lancet Oncol 14:590\u2013598. doi: 10.1016\/S1470-2045(13)70142-6","journal-title":"Lancet Oncol"},{"key":"3078_CR8","unstructured":"National Comprehensive Cancer Network (NCCN) (2013) Clinical practice guidelines in oncology-non-small cell lung cancer-version 2. http:\/\/www.nccn.org\/professionals\/physician_gls\/PDF\/antiemesis.pdf . Accessed 12 April 2015"},{"key":"3078_CR9","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/sj.bjc.6600725","volume":"88","author":"S Negoro","year":"2003","unstructured":"Negoro S, Masuda N, Takada Y et al (2003) Randomised phase III trial of irinotecan combined with cisplatin for advanced non-small-cell lung cancer. Br J Cancer 88:335\u2013341","journal-title":"Br J Cancer"},{"key":"3078_CR10","first-page":"S12-14","volume":"24","author":"FA Greco","year":"1997","unstructured":"Greco FA, Hainsworth JD (1997) Paclitaxel (1-hour infusion) plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicenter phase II trial. Semin Oncol 24:S12-14\u2013S12-17","journal-title":"Semin Oncol"},{"key":"3078_CR11","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1056\/NEJMoa011954","volume":"346","author":"JH Schiller","year":"2002","unstructured":"Schiller JH, Harrington D, Belani CP et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92\u201398","journal-title":"N Engl J Med"},{"key":"3078_CR12","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1093\/annonc\/mdl377","volume":"18","author":"Y Ohe","year":"2007","unstructured":"Ohe Y, Ohashi Y, Kubota K et al (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18:317\u2013323","journal-title":"Ann Oncol"},{"key":"3078_CR13","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","volume":"26","author":"GV Scagliotti","year":"2008","unstructured":"Scagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543\u20133551. doi: 10.1200\/JCO.2007.15.0375","journal-title":"J Clin Oncol"},{"key":"3078_CR14","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1200\/JCO.2004.00.9720","volume":"24","author":"AC Mita","year":"2006","unstructured":"Mita AC, Sweeney CJ, Baker SD et al (2006) Phase I and pharmacokinetic study of pemetrexed administered every 3\u00a0weeks to advanced cancer patients with normal and impaired renal function. J Clin Oncol 24:552\u2013562","journal-title":"J Clin Oncol"},{"key":"3078_CR15","first-page":"705","volume":"42","author":"N Funaguchi","year":"2015","unstructured":"Funaguchi N, Nakajima Y, Kaito D et al (2015) Analysis of pemetrexed monotherapy in advanced non-small cell lung cancer patients with impaired renal function. Gan To Kagaku Ryoho 42:705\u2013708","journal-title":"Gan To Kagaku Ryoho"},{"key":"3078_CR16","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1248\/yakushi.13-00180","volume":"133","author":"Y Sakata","year":"2013","unstructured":"Sakata Y, Iwamoto Y, Abe K, Miyamori S, Inata J, Kanehara M, Hiraki K (2013) Analysis of risk factors for severe adverse events of chemotherapy with pemetrexed and comparison of adverse event occurrence according to renal function. Yakugaku Zasshi 133:1209\u20131213","journal-title":"Yakugaku Zasshi"},{"key":"3078_CR17","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1470-2045(12)70063-3","volume":"13","author":"L Paz-Ares","year":"2012","unstructured":"Paz-Ares L, de Marinis F, Dediu M et al (2012) Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol 13:247\u2013255. doi: 10.1016\/S1470-2045(12)70063-3","journal-title":"Lancet Oncol"},{"key":"3078_CR18","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1200\/JCO.2012.47.1102","volume":"31","author":"LG Paz-Ares","year":"2013","unstructured":"Paz-Ares LG, de Marinis F, Dediu M et al (2013) PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 31:2895\u20132902. doi: 10.1200\/JCO.2012.47.1102","journal-title":"J Clin Oncol"},{"key":"3078_CR19","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gumbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748\u20131756","journal-title":"J Clin Oncol"},{"key":"3078_CR20","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1038\/bjc.1997.509","volume":"76","author":"Y Ando","year":"1997","unstructured":"Ando Y, Minami H, Saka H, Ando M, Sakai S, Shimokata K (1997) Adjustment of creatinine clearance improves accuracy of Calvert\u2019s formula for carboplatin dosing. Br J Cancer 76:1067\u20131071","journal-title":"Br J Cancer"},{"key":"3078_CR21","first-page":"4733","volume":"6","author":"M Ando","year":"2000","unstructured":"Ando M, Minami H, Ando Y et al (2000) Multi institutional validation study of carboplatin dosing formula using adjusted serum creatinine level. Clin Cancer Res 6:4733\u20134738","journal-title":"Clin Cancer Res"},{"key":"3078_CR22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/sj.bjc.6603321","volume":"95","author":"K Nakagawa","year":"2006","unstructured":"Nakagawa K, Kudoh S, Matsui K et al (2006) A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. Br J Cancer 95:677\u2013682","journal-title":"Br J Cancer"},{"key":"3078_CR23","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21:2636\u20132644","journal-title":"J Clin Oncol"},{"key":"3078_CR24","first-page":"545","volume":"1","author":"C Niyikiza","year":"2002","unstructured":"Niyikiza C, Baker SD, Seitz DE et al (2002) Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 1:545\u2013552","journal-title":"Mol Cancer Ther"},{"key":"3078_CR25","first-page":"2587","volume":"41","author":"M Kono","year":"2014","unstructured":"Kono M, Sakata Y, Sugawara T et al (2014) Assessment of risk factors for adverse events due to pemetrexed in patients with reduced renal function. Gan To Kagaku Ryoho 41:2587\u20132590","journal-title":"Gan To Kagaku Ryoho"},{"key":"3078_CR26","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1124\/dmd.114.059618","volume":"43","author":"MM Posada","year":"2015","unstructured":"Posada MM, Bacon JA, Schneck KB et al (2015) Prediction of renal transporter mediated drug-drug interactions for pemetrexed using physiologically based pharmacokinetic modeling. Drug Metab Dispos 43:325\u2013334. doi: 10.1124\/dmd.114.059618","journal-title":"Drug Metab Dispos"},{"key":"3078_CR27","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1200\/JCO.2014.58.4391","volume":"33","author":"R Kitagawa","year":"2015","unstructured":"Kitagawa R, Katsumata N, Shibata T et al (2015) Paclitaxel plus carboplatin versus paclitaxel plus cisplatin in metastatic or recurrent cervical cancer: the open-label randomized phase III trial JCOG0505. J Clin Oncol 33:2129\u20132135. doi: 10.1200\/JCO.2014.58.4391","journal-title":"J Clin Oncol"},{"key":"3078_CR28","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194\u20133200","journal-title":"J Clin Oncol"},{"key":"3078_CR29","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/annonc\/mdf332","volume":"13","author":"R Rosell","year":"2002","unstructured":"Rosell R, Gatzemeier U, Betticher DC et al (2002) Phase III randomised trial comparing paclitaxel\/carboplatin with paclitaxel\/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 13:1539\u20131549","journal-title":"Ann Oncol"},{"key":"3078_CR30","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cllc.2012.10.001","volume":"14","author":"WH Schuette","year":"2013","unstructured":"Schuette WH, Gr\u00f6schel A, Sebastian M et al (2013) A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non-small-cell lung cancer. Clin Lung Cancer 14:215\u2013223. doi: 10.1016\/j.cllc.2012.10.001","journal-title":"Clin Lung Cancer"},{"key":"3078_CR31","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/geronj\/31.2.155","volume":"31","author":"JW Rowe","year":"1976","unstructured":"Rowe JW, Andres R, Tobin JD et al (1976) The effect of age on creatinine clearance in men: a cross-sectional and longitudinal study. J Gerontol 31:155\u2013163","journal-title":"J Gerontol"},{"key":"3078_CR32","volume-title":"Drug prescribing in renal failure","author":"GR Aronoff","year":"2007","unstructured":"Aronoff GR, Bennett WM, Berns JS et al (2007) Drug prescribing in renal failure, 5th edn. American College of Physicians, Philadelphia","edition":"5"},{"key":"3078_CR33","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/clpt.1988.132","volume":"44","author":"G Daugaard","year":"1988","unstructured":"Daugaard G, Abildgaard U, Holstein-Rathlou NH, Bruunshuus I, Bucher D, Leyssac PP (1988) Renal tubular function in patients treated with high-dose cisplatin. Clin Pharmacol Ther 44:164\u2013172","journal-title":"Clin Pharmacol Ther"},{"key":"3078_CR34","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1093\/jjco\/hyu003","volume":"44","author":"A Matsuda","year":"2014","unstructured":"Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H, Japan Cancer Surveillance Research Group (2014) Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol 44:388\u2013396. doi: 10.1093\/jjco\/hyu003","journal-title":"Jpn J Clin Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3078-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-016-3078-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-016-3078-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T16:09:24Z","timestamp":1498320564000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-016-3078-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,10]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["3078"],"URL":"https:\/\/doi.org\/10.1007\/s00280-016-3078-7","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,10]]}}}